COMBINATION OF ANTIBODY AGAINST HGFR AND HEGFR FOR TREATMENT OF TUMOR AND/OR METASTASIS Russian patent published in 2023 - IPC C07K16/28 A61K38/17 A61K39/395 C07K14/71 C12N15/62 C07K19/00 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to a new combination of therapeutic agents for the treatment of tumor and/or metastasis. The use of a combination of a fragment of an antibody against a hepatocyte growth factor receptor (hereinafter – HGFR) and an extracellular part of human HGFR in the treatment of a patient suffering from HGF-secreting tumor and/or metastasis, preferably HGF-secreting metastasis, is proposed. Fused protein having activity of simultaneous HGFR antagonism and HGF binding, containing, in a direction from N- to C-end, (i) a fragment of an antibody against HGFR, a linker, and an extracellular part of human HGFR; or (ii) an extracellular part of human HGFR, a linker, and a fragment of an antibody against HGFR, a nucleic acid molecule encoding fused protein, and a pharmaceutical composition containing fused protein and a pharmaceutically acceptable carrier are also proposed.

EFFECT: inventions allow for double targeting a hepatocyte growth factor (HGF) and a hepatocyte growth factor receptor (HGFR), simultaneously acting on MET-expressing cancer cells and on HGF-secreting tumor stroma and exerting a synergetic effect in the treatment of tumors and/or metastasis.

14 cl, 13 dwg